In a patient recovering from cocaine/crack dependence who requests ADHD medication but has no documented childhood ADHD history, how should ADHD be evaluated and what pharmacologic treatment is recommended?

ADHD Evaluation and Treatment in Recovering Cocaine/Crack Users

In a patient recovering from cocaine/crack dependence requesting ADHD medication without documented childhood history, you should conduct a comprehensive ADHD assessment requiring collateral information from multiple sources to confirm childhood-onset symptoms, and if ADHD is confirmed, initiate treatment with atomoxetine as first-line therapy rather than stimulants, given the safer profile in this population.

Diagnostic Evaluation Requirements

The diagnosis of ADHD requires documented evidence of symptoms beginning in childhood, ideally before age 12, obtained from multiple informants across different settings 1. In adults presenting without childhood documentation:

• Obtain collateral information from parents, significant others, or friends who knew the patient during childhood - adults with ADHD often have poor insight and underestimate their symptom severity 1
• Gather information from at least two adult sources from different settings to document impairment in multiple domains 1
• Use structured rating scales including the Wender Parent's Rating Scale, Wender Utah Rating Scales, Brown Attention-Deficit Disorder Scale for Adults, or Conners Adult ADHD Rating Scale 1
• Document moderate to severe impairment in at least two different settings (occupational, social, family functioning) to justify pharmacological treatment 1

Critical Assessment for Substance Use

Before initiating any ADHD medication, you must assess for active substance use and obtain a detailed drug and alcohol history 2, 1:

• Consider obtaining a urine drug screen to rule out active substance use 1
• If active substance use is identified, refer to a subspecialist for consultative support before starting ADHD medication 2
• Ensure the patient is in stable recovery before considering pharmacotherapy

Differential Diagnosis Considerations

Rule out conditions that may masquerade as ADHD 1:

• Bipolar disorder
• Depression
• Personality disorders (particularly antisocial personality disorder, which is independently associated with cocaine use disorder) 3
• Learning disabilities
• Undiagnosed borderline intellectual functioning
• Residual effects of chronic stimulant use

Pharmacological Treatment Recommendations

First-Line: Atomoxetine (Non-Stimulant)

Atomoxetine should be the first-line medication for ADHD in patients with cocaine/crack use disorder history due to its lack of abuse potential 2, 4:

• Atomoxetine is recommended to improve ADHD symptoms in patients with comorbid substance use disorders (weak recommendation) 4
• Atomoxetine appears to be safe in patients with any substance use disorder (strong recommendation) 4
• In patients with ADHD and cocaine use disorder specifically, atomoxetine is recommended to improve ADHD symptoms (weak recommendation), though it is not effective for reducing cocaine use itself 4
• Atomoxetine minimizes abuse potential, making it preferable in populations at risk for diversion or misuse 2

Second-Line: Stimulant Medications (With Caution)

If atomoxetine is ineffective or not tolerated, stimulant medications can be considered but require careful monitoring 4, 5:

• Psychostimulants (methylphenidate or lisdexamfetamine) are recommended to improve ADHD symptoms in patients with substance use disorders (weak recommendation) but not to reduce substance use (weak recommendation) 4
• Recent trials using robust dosing of psychostimulants have demonstrated significantly positive results in ADHD-SUD populations 5
• High doses of stimulant medications (up to 60mg methylphenidate) have mild to moderate efficacy on ADHD symptoms in ADHD-SUD subjects 6
• Methylphenidate maintenance can decrease some positive and reinforcing effects of cocaine in cocaine abusers with ADHD 7

Stimulant Safety Considerations in This Population

When prescribing stimulants to patients with cocaine/crack history, implement strict monitoring protocols 2, 6:

• Monitor for signs of misuse or diversion at each prescription refill 2
• Consider longer-acting formulations to reduce abuse potential 2
• Cardiovascular effects may be increased when stimulants are combined with cocaine use, though this has not warranted session termination in research settings 7
• In the long run, stimulant medications may have potential risk for misuse despite short-term safety 6

Treatment Initiation Protocol

Start with conservative dosing and titrate based on response 1:

• For methylphenidate: start with 5mg doses given 2-3 times daily due to short duration of action 1
• For amphetamines: start with 2.5mg doses 1
• Increase in weekly increments of 5-10mg per dose for methylphenidate or 2.5-5mg for amphetamines if symptom control is not achieved 1
• Maximum total daily doses: 60mg for methylphenidate, 40mg for amphetamines per PDR recommendations, though clinical practice may occasionally exceed these limits 1

Monitoring Requirements

Establish a structured follow-up schedule 1:

• Weekly contact during initial titration phase (2-4 weeks) by telephone or in-person 1
• At least monthly appointments until symptoms are stabilized 1
• More frequent appointments if there are side effects, significant psychiatric comorbidity, or adherence problems 1
• Systematically assess side effects including insomnia, anorexia, headaches, social withdrawal, tics, and weight loss 1
• Obtain teacher/workplace ratings using validated instruments at baseline and after treatment 1

Critical Pitfalls to Avoid

Do not prescribe ADHD medications if the patient does not meet full DSM criteria for ADHD - medication is not appropriate for subthreshold symptoms 2

Do not assume cocaine use was self-medication for ADHD without proper diagnostic confirmation - while some patients report paradoxical calming effects from cocaine (which increases diagnostic suspicion of ADHD) 3, this alone does not confirm the diagnosis

Do not initiate stimulant treatment during active substance use - refer to subspecialist first 2

Recognize that ADHD treatment alone will not address addictive behavior - combine ADHD pharmacotherapy with SUD-specific treatment strategies 6

Be aware that late initiation of stimulant therapy (≥10 years old) and short duration (<1 year) is associated with higher odds of prescription stimulant misuse 8, suggesting this patient population requires particularly careful monitoring